Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Healthcare leaders, policymakers, hospitals, and patient advocates discuss AI-driven healthcare, digital transformation, quality of life in cancer care
With 267 million tobacco users, improving access to evidence-based cessation tools is seen as critical
The private funding rose 38% amid growing international collaborations and CDMO demand
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
